arrow
S

Silvio E. Inzucchi

Yale University School of Medicine
H指数:0
被引数:501

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining Severe Heart Failure across the Ejection Fraction Spectrum in DAPA-HF and DELIVER

在DAPA-HF和DELIVER研究中,根据射血分数谱定义重度心力衰竭

2024-11-120
PRE
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVER
2024-07-172
OA
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial
2024-05-151
OA
Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction
2024-05-030
OAAI
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
2024-05-012
PRE
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER

Dapagliflozin在心力衰竭和既往心肌梗死患者中的应用: dapa-hf和deliverse的参与者水平汇总分析

2024-03-153
OA
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction A Post Hoc Analysis of the DELIVER Trial
2024-03-016
OAAI
Initial Decline in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Insights From DELIVER
2023-11-070
PRE
Microvascular Complications of Type 2 Diabetes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction in the DELIVER Trial
2023-11-070
PRE
Effects of Dapagliflozin in Heart Failure, Type 2 Diabetes, and Neuropathy - A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
2023-11-070
PRE
Efficacy and Safety of Dapagliflozin in Patients With Heart Failure and Previous Myocardial Infarction

达格列净在心力衰竭和既往心肌梗死患者中的疗效和安全性

2023-11-070
PRE